文献速递自身炎症与 IgG4 相关病

COVID-19中的细胞因子风暴:不同病因的相似风暴需警惕

Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.
PubMed 文献 · RMD Open · 2020-01-01

该观点文章讨论COVID-19中细胞因子风暴的异质性,指出部分患者发展为继发性噬血细胞性淋巴组织细胞增多症(sHLH),另一些患者虽不符合sHLH标准但表现类似高铁蛋白综合征。文章还涉及儿童多系统炎症性疾病及将COVID-19纳入高铁蛋白综合征谱系的论点。

要点

  • COVID-19中高炎症反应异质,部分符合sHLH,部分类似高铁蛋白综合征。
  • 免疫调节剂使用时需考虑病毒载量和细胞因子/铁蛋白过表达程度。
  • 儿童SARS-CoV-2感染后可见类似中毒性休克和非典型川崎病的多系统炎症病。

核心结论

  • COVID-19中的细胞因子风暴与其他病因所致sHLH共享终末事件,但病因差异导致各阶段表现不同。
  • 高炎症微环境为重型COVID-19使用免疫调节剂提供了依据。
  • 建议将COVID-19纳入高铁蛋白综合征谱系。

研究设计与样本

  • 观点文章,讨论COVID-19中免疫调节剂使用的陷阱与问题。

主要发现

  • 部分COVID-19患者发展为完全型继发性HLH,另一些不符合sHLH标准但类似高铁蛋白综合征表型。
  • 儿童SARS-CoV-2感染后可见类似中毒性休克综合征和非典型川崎病的多系统炎症病。

关键数值与推荐

  • 免疫调节剂治疗时机需基于病毒载量和细胞因子/铁蛋白过表达程度。

临床怎么用

  • 临床使用免疫调节剂治疗重型COVID-19时需权衡时机与患者高炎症程度。
  • 对儿童SARS-CoV-2感染后多系统炎症病需保持警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Some of the articles being published during the severe acute respiratory syndrome-coronavirus (SARS-CoV)-2 pandemic highlight a link between severe forms of coronavirus disease 2019 (COVID-19) and the so-called cytokine storm, also with increased ferritin levels. However, this scenario is more complex than initially thought due to the heterogeneity of hyperinflammation. Some patients with coronavirus 2019 disease (COVID-19) develop a fully blown secondary haemophagocytic lymphohistiocytosis (sHLH), whereas others, despite a consistent release of pro-inflammatory cytokines, do not fulfil sHLH criteria but still show some features resembling the phenotype of the hyperferritinemic syndrome. Despite the final event (the cytokine storm) is shared by various conditions leading to sHLH, the aetiology, either infectious, autoimmune or neoplastic, accounts for the differences in the various phases of this process. Moreover, the evidence of a hyperinflammatory microenvironment provided the rationale to employ immunomodulating agents for therapeutic purposes in severe COVID-19. This viewpoint aims at discussing the pitfalls and issues to be considered with regard to the use of immunomodulating agents in COVID-19, such as timing of treatment based on the viral load and the extent of cytokine/ferritin overexpression. Furthermore, it encompasses recent findings in the paediatric field about a novel multisystem inflammatory disease resembling toxic shock syndrome and atypical Kawasaki disease observed in children with proven SARS-CoV2 infection. Finally, it includes arguments in favour of adding COVID-19 to the spectrum of the recently defined 'hyperferritinemic syndrome', which already includes adult-onset Still's disease, macrophage activation syndrome, septic shock and catastrophic anti-phospholipid syndrome.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Alunno A, Carubbi F, Rodríguez-Carrio J, et al. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. RMD Open. 2020. PMID: 32423970. doi:10.1136/rmdopen-2020-001295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。